Postmenopausal hormone use and risk for colorectal cancer and adenoma

Francine Grodstein, M. Elena Martinez, Elizabeth A Platz, Edward Giovannucci, Graham A. Colditz, Mira Kautzky, Charles Fuchs, Meir J. Stampfer

Research output: Contribution to journalArticle

Abstract

Background: Accumulating evidence suggests that postmenopausal hormone use may decrease the risk for colorectal cancer. Objective: To examine the relation of postmenopausal hormone therapy to colorectal adenoma and cancer. Design: Prospective cohort and nested case-control studies. Setting: Nurses' Health Study, a study of registered nurses recruited from 11 U.S. states. Participants: 59 002 postmenopausal participants in the Nurses' Health Study. Measurements: Self-reported data on hormone use and cases of distal colorectal adenoma and colorectal cancer obtained from biennial questionnaires completed from 1980 to 1994. Cases of colorectal adenoma and cancer were confirmed by medical record review. Results: 470 women developed colorectal cancer, and 838 developed distal colorectal adenomas. Current use of postmenopausal hormones was associated with a decreased risk for colorectal cancer (relative risk [RR], 0.65 [95% CI, 0.50 to 0.83]). This association was attenuated in past users (RR, 0.84 [CI, 0.67 to 1.05]) and disappeared 5 years after hormone use was discontinued (RR, 0.92 [CI, 0.70 to 1.21]). Longer duration of current use did not afford greater protection (RR with ≤5 years of use, 0.72 [CI, 0.53 to 0.96]). Even after exclusion of women who reported having screening sigmoidoscopy, the relative risk for colorectal cancer seen with current hormone use was 0.64 (CI, 0.49 to 0.82). This suggests that the apparent protection is unlikely to be due to more intensive screening among hormone users. Current users also had a lower risk for large (≤1 cm) adenomas than did women who had never used hormones (RR, 0.74 [CI, 0.55 to 0.99]), although no overall material association was seen between colorectal adenoma and current hormone use (RR, 0.91 [CI, 0.77 to 1.08]). Conclusions: The risk for colorectal cancer was decreased among women currently receiving postmenopausal hormone therapy, but the apparent reduction substantially diminished upon cessation of therapy. Hormone use was inversely associated with large colorectal adenomas but not small ones.

Original languageEnglish (US)
Pages (from-to)705-712
Number of pages8
JournalAnnals of Internal Medicine
Volume128
Issue number9
StatePublished - May 1 1998
Externally publishedYes

Fingerprint

Adenoma
Colorectal Neoplasms
Hormones
Nurses
Sigmoidoscopy
Health
Medical Records
Case-Control Studies
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Grodstein, F., Martinez, M. E., Platz, E. A., Giovannucci, E., Colditz, G. A., Kautzky, M., ... Stampfer, M. J. (1998). Postmenopausal hormone use and risk for colorectal cancer and adenoma. Annals of Internal Medicine, 128(9), 705-712.

Postmenopausal hormone use and risk for colorectal cancer and adenoma. / Grodstein, Francine; Martinez, M. Elena; Platz, Elizabeth A; Giovannucci, Edward; Colditz, Graham A.; Kautzky, Mira; Fuchs, Charles; Stampfer, Meir J.

In: Annals of Internal Medicine, Vol. 128, No. 9, 01.05.1998, p. 705-712.

Research output: Contribution to journalArticle

Grodstein, F, Martinez, ME, Platz, EA, Giovannucci, E, Colditz, GA, Kautzky, M, Fuchs, C & Stampfer, MJ 1998, 'Postmenopausal hormone use and risk for colorectal cancer and adenoma', Annals of Internal Medicine, vol. 128, no. 9, pp. 705-712.
Grodstein F, Martinez ME, Platz EA, Giovannucci E, Colditz GA, Kautzky M et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Annals of Internal Medicine. 1998 May 1;128(9):705-712.
Grodstein, Francine ; Martinez, M. Elena ; Platz, Elizabeth A ; Giovannucci, Edward ; Colditz, Graham A. ; Kautzky, Mira ; Fuchs, Charles ; Stampfer, Meir J. / Postmenopausal hormone use and risk for colorectal cancer and adenoma. In: Annals of Internal Medicine. 1998 ; Vol. 128, No. 9. pp. 705-712.
@article{175d0cb004154d699771f61aacbf13ff,
title = "Postmenopausal hormone use and risk for colorectal cancer and adenoma",
abstract = "Background: Accumulating evidence suggests that postmenopausal hormone use may decrease the risk for colorectal cancer. Objective: To examine the relation of postmenopausal hormone therapy to colorectal adenoma and cancer. Design: Prospective cohort and nested case-control studies. Setting: Nurses' Health Study, a study of registered nurses recruited from 11 U.S. states. Participants: 59 002 postmenopausal participants in the Nurses' Health Study. Measurements: Self-reported data on hormone use and cases of distal colorectal adenoma and colorectal cancer obtained from biennial questionnaires completed from 1980 to 1994. Cases of colorectal adenoma and cancer were confirmed by medical record review. Results: 470 women developed colorectal cancer, and 838 developed distal colorectal adenomas. Current use of postmenopausal hormones was associated with a decreased risk for colorectal cancer (relative risk [RR], 0.65 [95{\%} CI, 0.50 to 0.83]). This association was attenuated in past users (RR, 0.84 [CI, 0.67 to 1.05]) and disappeared 5 years after hormone use was discontinued (RR, 0.92 [CI, 0.70 to 1.21]). Longer duration of current use did not afford greater protection (RR with ≤5 years of use, 0.72 [CI, 0.53 to 0.96]). Even after exclusion of women who reported having screening sigmoidoscopy, the relative risk for colorectal cancer seen with current hormone use was 0.64 (CI, 0.49 to 0.82). This suggests that the apparent protection is unlikely to be due to more intensive screening among hormone users. Current users also had a lower risk for large (≤1 cm) adenomas than did women who had never used hormones (RR, 0.74 [CI, 0.55 to 0.99]), although no overall material association was seen between colorectal adenoma and current hormone use (RR, 0.91 [CI, 0.77 to 1.08]). Conclusions: The risk for colorectal cancer was decreased among women currently receiving postmenopausal hormone therapy, but the apparent reduction substantially diminished upon cessation of therapy. Hormone use was inversely associated with large colorectal adenomas but not small ones.",
author = "Francine Grodstein and Martinez, {M. Elena} and Platz, {Elizabeth A} and Edward Giovannucci and Colditz, {Graham A.} and Mira Kautzky and Charles Fuchs and Stampfer, {Meir J.}",
year = "1998",
month = "5",
day = "1",
language = "English (US)",
volume = "128",
pages = "705--712",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "9",

}

TY - JOUR

T1 - Postmenopausal hormone use and risk for colorectal cancer and adenoma

AU - Grodstein, Francine

AU - Martinez, M. Elena

AU - Platz, Elizabeth A

AU - Giovannucci, Edward

AU - Colditz, Graham A.

AU - Kautzky, Mira

AU - Fuchs, Charles

AU - Stampfer, Meir J.

PY - 1998/5/1

Y1 - 1998/5/1

N2 - Background: Accumulating evidence suggests that postmenopausal hormone use may decrease the risk for colorectal cancer. Objective: To examine the relation of postmenopausal hormone therapy to colorectal adenoma and cancer. Design: Prospective cohort and nested case-control studies. Setting: Nurses' Health Study, a study of registered nurses recruited from 11 U.S. states. Participants: 59 002 postmenopausal participants in the Nurses' Health Study. Measurements: Self-reported data on hormone use and cases of distal colorectal adenoma and colorectal cancer obtained from biennial questionnaires completed from 1980 to 1994. Cases of colorectal adenoma and cancer were confirmed by medical record review. Results: 470 women developed colorectal cancer, and 838 developed distal colorectal adenomas. Current use of postmenopausal hormones was associated with a decreased risk for colorectal cancer (relative risk [RR], 0.65 [95% CI, 0.50 to 0.83]). This association was attenuated in past users (RR, 0.84 [CI, 0.67 to 1.05]) and disappeared 5 years after hormone use was discontinued (RR, 0.92 [CI, 0.70 to 1.21]). Longer duration of current use did not afford greater protection (RR with ≤5 years of use, 0.72 [CI, 0.53 to 0.96]). Even after exclusion of women who reported having screening sigmoidoscopy, the relative risk for colorectal cancer seen with current hormone use was 0.64 (CI, 0.49 to 0.82). This suggests that the apparent protection is unlikely to be due to more intensive screening among hormone users. Current users also had a lower risk for large (≤1 cm) adenomas than did women who had never used hormones (RR, 0.74 [CI, 0.55 to 0.99]), although no overall material association was seen between colorectal adenoma and current hormone use (RR, 0.91 [CI, 0.77 to 1.08]). Conclusions: The risk for colorectal cancer was decreased among women currently receiving postmenopausal hormone therapy, but the apparent reduction substantially diminished upon cessation of therapy. Hormone use was inversely associated with large colorectal adenomas but not small ones.

AB - Background: Accumulating evidence suggests that postmenopausal hormone use may decrease the risk for colorectal cancer. Objective: To examine the relation of postmenopausal hormone therapy to colorectal adenoma and cancer. Design: Prospective cohort and nested case-control studies. Setting: Nurses' Health Study, a study of registered nurses recruited from 11 U.S. states. Participants: 59 002 postmenopausal participants in the Nurses' Health Study. Measurements: Self-reported data on hormone use and cases of distal colorectal adenoma and colorectal cancer obtained from biennial questionnaires completed from 1980 to 1994. Cases of colorectal adenoma and cancer were confirmed by medical record review. Results: 470 women developed colorectal cancer, and 838 developed distal colorectal adenomas. Current use of postmenopausal hormones was associated with a decreased risk for colorectal cancer (relative risk [RR], 0.65 [95% CI, 0.50 to 0.83]). This association was attenuated in past users (RR, 0.84 [CI, 0.67 to 1.05]) and disappeared 5 years after hormone use was discontinued (RR, 0.92 [CI, 0.70 to 1.21]). Longer duration of current use did not afford greater protection (RR with ≤5 years of use, 0.72 [CI, 0.53 to 0.96]). Even after exclusion of women who reported having screening sigmoidoscopy, the relative risk for colorectal cancer seen with current hormone use was 0.64 (CI, 0.49 to 0.82). This suggests that the apparent protection is unlikely to be due to more intensive screening among hormone users. Current users also had a lower risk for large (≤1 cm) adenomas than did women who had never used hormones (RR, 0.74 [CI, 0.55 to 0.99]), although no overall material association was seen between colorectal adenoma and current hormone use (RR, 0.91 [CI, 0.77 to 1.08]). Conclusions: The risk for colorectal cancer was decreased among women currently receiving postmenopausal hormone therapy, but the apparent reduction substantially diminished upon cessation of therapy. Hormone use was inversely associated with large colorectal adenomas but not small ones.

UR - http://www.scopus.com/inward/record.url?scp=0032079867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032079867&partnerID=8YFLogxK

M3 - Article

C2 - 9556463

AN - SCOPUS:0032079867

VL - 128

SP - 705

EP - 712

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 9

ER -